Efficacy and safety of ultrasound-guided microwave ablation versus surgical resection for Bethesda category IV thyroid nodules: A retrospective comparative study

Bibliographic Details
Title: Efficacy and safety of ultrasound-guided microwave ablation versus surgical resection for Bethesda category IV thyroid nodules: A retrospective comparative study
Authors: Jingjing Yang, Ya Zhang, Xingjia Li, Yueting Zhao, Xue Han, Guofang Chen, Xiaoqiu Chu, Ruiping Li, Jianhua Wang, Fei Huang, Chao Liu, Shuhang Xu
Source: Frontiers in Endocrinology, Vol 13 (2022)
Publisher Information: Frontiers Media S.A., 2022.
Publication Year: 2022
Collection: LCC:Diseases of the endocrine glands. Clinical endocrinology
Subject Terms: thyroid nodule, the Bethesda system for reporting thyroid cytology, microwave ablation, thyroidectomy, follicular neoplasm (FN)/suspicious for follicular neoplasm (SFN), Diseases of the endocrine glands. Clinical endocrinology, RC648-665
More Details: ObjectiveThe objective of this study was to assess the efficacy and safety of ultrasound-guided microwave ablation (MWA) for Bethesda IV thyroid nodules and to compare the outcomes, complications, and costs of MWA and thyroidectomy.MethodsA total of 130 patients with Bethesda IV nodules were retrospectively reviewed, involving 46 in the MWA group and 84 in the surgery group. The local institutional review board approved this study. Patients in the MWA group were followed up at 1, 3, 6, and 12 months after the intervention. Postoperative complications, treatment time, and cost in the two groups were compared.ResultsAmong 84 patients with 85 Bethesda IV nodules in the surgery group, postoperative pathology was benign lesions, borderline tumors, papillary thyroid carcinoma, follicular variant papillary thyroid carcinoma, follicular thyroid carcinoma, and medullary carcinoma in 44, 4, 27, 6, 3, and 1 cases, respectively. Malignant thyroid nodules were more prone to solid echostructure (86.11% vs. 72.72%), hypoechogenicity (55.56% vs. 13.63%), and irregular margin (47.22% vs. 13.63%) than benign lesions. The nodule volume reduction rate of patients at 12 months after MWA was 85.01% ± 10.86%. Recurrence and lymphatic and distant metastases were not reported during the follow-up period. The incidence of complications, treatment time, hospitalization time, incision length, and cost were significantly lower in the MWA group than in the surgery group (all p < 0.001).ConclusionsMWA significantly reduces the volume of Bethesda IV nodules with high safety and is recommended for those with surgical contraindications or those who refuse surgical resection. Patients with suspicious ultrasound features for malignancy should be actively treated with surgery.
Document Type: article
File Description: electronic resource
Language: English
ISSN: 1664-2392
Relation: https://www.frontiersin.org/articles/10.3389/fendo.2022.924993/full; https://doaj.org/toc/1664-2392
DOI: 10.3389/fendo.2022.924993
Access URL: https://doaj.org/article/a411dccb9ea7456485e1dc7c8799e53c
Accession Number: edsdoj.411dccb9ea7456485e1dc7c8799e53c
Database: Directory of Open Access Journals
More Details
ISSN:16642392
DOI:10.3389/fendo.2022.924993
Published in:Frontiers in Endocrinology
Language:English